Polymeric Nanovaccines for Immune Modulation

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (10 March 2022) | Viewed by 9533

Special Issue Editors


E-Mail Website
Guest Editor
Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, USA
Interests: nanomaterials; nanomedicine; immunotherapy; nanovaccines
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Biomedical Sciences, Chonnam National University Medical School, 160 Baekseo-ro, Gwangju 58128, Korea
Interests: stimulus-responsive nanoparticles; nanoparticle-based vaccine delivery; photo-immunotherapy

Special Issue Information

Dear Colleagues,

Vaccination is one of the most effective ways to cure human diseases. With the advancements in science and technology, nanovaccines comprising nanoparticles that are either used as adjuvants or carriers has emerged as one of the most effective treatment strategies for health promotion and disease prevention. Nanovaccines are reported to be highly efficient in inducing humoral and cell-mediated immune responses and demonstrate high antigen loading, enhanced immunogenicity, and controlled antigen presentation. Polymers from the natural or synthetic route are often used for developing nanovaccines which could be easily internalized by antigen-presenting cells and exert immune modulations owing to the unique physiochemical properties of nanoparticles.

We are calling for manuscripts detailing natural and synthetic polymeric nanovaccines, anticancer nanovaccine delivery systems, immune modulating polymeric nanoparticles, etc. We sincerely hope this Special Issue serves as a platform for the exchange of the latest developments in the field of polymeric nano vaccines.

Dr. Saji Uthaman
Prof. Dr. In-Kyu Park
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • polymeric nanovaccines
  • anticancer nanovaccines
  • infection and immunity
  • humoral and cell-mediated immunity

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 1789 KiB  
Review
A Review of Different Vaccines and Strategies to Combat COVID-19
by Srinivasan Sabitha, Nagarajan Shobana, Pandurangan Prakash, Sathiyamoorthy Padmanaban, Mahendran Sathiyashree, Subramanian Saigeetha, Srikumar Chakravarthi, Saji Uthaman, In-Kyu Park and Antony V. Samrot
Vaccines 2022, 10(5), 737; https://doi.org/10.3390/vaccines10050737 - 9 May 2022
Cited by 12 | Viewed by 3984
Abstract
In December 2019, an unknown viral infection emerged and quickly spread worldwide, resulting in a global pandemic. This novel virus caused severe pneumonia and acute respiratory distress syndrome caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It has caused 6.25 millions of [...] Read more.
In December 2019, an unknown viral infection emerged and quickly spread worldwide, resulting in a global pandemic. This novel virus caused severe pneumonia and acute respiratory distress syndrome caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It has caused 6.25 millions of deaths worldwide and remains a major concern for health, society, and the economy. As vaccination is one of the most efficient ways to combat this pandemic, different vaccines were developed in a short period. This review article discusses how coronavirus affected the top nations of the world and the vaccines being used for the prevention. Amongst the vaccines, some vaccines have already been approved, and some have been involved in clinical studies. The article also provides insight into different COVID-19 vaccine platforms, their preparation, working, efficacy, and side effects. Full article
(This article belongs to the Special Issue Polymeric Nanovaccines for Immune Modulation)
Show Figures

Figure 1

23 pages, 2948 KiB  
Review
Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy—Current Status and Future Perspectives
by Ramar Thangam, Kapil D. Patel, Heemin Kang and Ramasamy Paulmurugan
Vaccines 2021, 9(8), 935; https://doi.org/10.3390/vaccines9080935 - 23 Aug 2021
Cited by 21 | Viewed by 4539
Abstract
Engineering polymeric nanoparticles for their shape, size, surface chemistry, and functionalization using various targeting molecules has shown improved biomedical applications for nanoparticles. Polymeric nanoparticles have created tremendous therapeutic platforms, particularly applications related to chemo- and immunotherapies in cancer. Recently advancements in immunotherapies have [...] Read more.
Engineering polymeric nanoparticles for their shape, size, surface chemistry, and functionalization using various targeting molecules has shown improved biomedical applications for nanoparticles. Polymeric nanoparticles have created tremendous therapeutic platforms, particularly applications related to chemo- and immunotherapies in cancer. Recently advancements in immunotherapies have broadened this field in immunology and biomedical engineering, where “immunoengineering” creates solutions to target translational science. In this regard, the nanoengineering field has offered the various techniques necessary to manufacture and assemble multifunctional polymeric nanomaterial systems. These include nanoparticles functionalized using antibodies, small molecule ligands, targeted peptides, proteins, and other novel agents that trigger and encourage biological systems to accept the engineered materials as immune enhancers or as vaccines to elevate therapeutic functions. Strategies to engineer polymeric nanoparticles with therapeutic and targeting molecules can provide solutions for developing immune vaccines via maintaining the receptor storage in T- and B cells. Furthermore, cancer immunotherapy using polymeric nanomaterials can serve as a gold standard approach for treating primary and metastasized tumors. The current status of the limited availability of immuno-therapeutic drugs highlights the importance of polymeric nanomaterial platforms to improve the outcomes via delivering anticancer agents at localized sites, thereby enhancing the host immune response in cancer therapy. This review mainly focuses on the potential scientific enhancements and recent developments in cancer immunotherapies by explicitly discussing the role of polymeric nanocarriers as nano-vaccines. We also briefly discuss the role of multifunctional nanomaterials for their therapeutic impacts on translational clinical applications. Full article
(This article belongs to the Special Issue Polymeric Nanovaccines for Immune Modulation)
Show Figures

Figure 1

Back to TopTop